United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa Sells 645 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 645 shares of the company’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director now directly owns 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Trading Down 1.4%

UTHR opened at $285.97 on Thursday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82. The firm has a market capitalization of $12.90 billion, a PE ratio of 11.41, a P/E/G ratio of 6.35 and a beta of 0.57. The firm has a 50 day moving average of $301.15 and a two-hundred day moving average of $326.23.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the company earned $6.17 EPS. As a group, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC grew its position in United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 30 shares in the last quarter. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 30 shares in the last quarter. Anchor Investment Management LLC grew its position in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares in the last quarter. Great Lakes Advisors LLC grew its position in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on UTHR. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an “overweight” rating and a $405.00 price target on the stock. Morgan Stanley upped their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 11th. Finally, Wall Street Zen lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $393.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.